Please provide your email address to receive an email when new articles are posted on . The FDA has approved bimekizumab-bkzx for three new indications — PsA, AS and non-radiographic axial SpA. The ...

- AbbVie has also submitted results from two studies of upadacitinib in adult patients with ankylosing spondylitis (AS) to request label enhancements in the European Union (EU) - RINVOQ is approved ...

No new safety risks were identified in the studies. Positive topline results were announced from the phase 3 SELECT-AXIS 2 study evaluating upadacitinib in adults with active ankylosing spondylitis ...

BRUSSELS and ATLANTA, Jan. 18, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met ...

The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy. The Food and Drug ...

OAKVILLE, ON, Jan. 15, 2020 /CNW/ - UCB Canada Inc. announced today that Health Canada has approved CIMZIA ® (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial ...

Full 1-year results have now been published for the pivotal SELECT-AXIS 2 trial that underpinned the FDA approval of upadacitinib (Rinvoq) for non-radiographic axial spondyloarthritis (axSpA), ...

Ankylosing Spondylitis (AS) is the leading chronic progressive inflammatory rheumatic disease that involves the sacroiliac joints (SIJs) and the spinal column but is often difficult to recognize in ...

The MarketWatch News Department was not involved in the creation of this content. Exton, PA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The 2025 Market Dynamix(TM): Psoriatic ...

There are certain symptoms that seem obviously linked together: If you have heartburn and regurgitation, the signs point to gastroesophageal reflux disease, or GERD. If you have bad headaches, nausea, ...